PURPOSE OF REVIEW:This article reviews recent developments in the use of active surveillance for localized prostate cancer.
RECENT FINDINGS: The treatment of localized prostate cancer continues to be a major challenge for urologic oncologists. Screening with prostate-specific antigen has resulted in increased numbers of low-risk prostate cancers being detected. Aggressive whole-gland therapy with surgery, or radiation therapy is associated with potentially life-altering treatment-related side effects such as urinary incontinence, bowel toxicity and erectile dysfunction. The goal of active surveillance is to avoid or delay the adverse events associated with prostate cancer therapy while still allowing for curative intervention in the future, if needed.
SUMMARY: Active surveillance is a reasonable treatment option for many men with low-risk, and some men with intermediate-risk, prostate cancer. Additional research is needed to determine the optimal active surveillance inclusion criteria, monitoring schedule, and treatment triggers. It is hoped that advances in prostate imaging, biomarkers, and focal therapy will foster greater use of active surveillance in appropriately selected men to optimize quality-of-life without compromising cancer outcomes.
Written by:
Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL. Are you the author?
Urologic Oncology Branch; Radiation Oncology Branch, Center for Cancer Research; Molecular Imaging Program; Medical Oncology Branch, Cancer Research Center; Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States.
Reference: Curr Opin Oncol. 2012 May;24(3):243-50.
doi: 10.1097/CCO.0b013e3283527f99
PubMed Abstract
PMID: 22450149
UroToday.com Prostate Cancer Section